Diabetes primary prevention program: new insights from data analysis of recruitment period by Gagliardino, Juan Jose et al.
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1002/dmrr.2943 
 
This article is protected by copyright. All rights reserved. 
DIABETES PRIMARY PREVENTION PROGRAM: NEW INSIGHTS FROM DATA 
ANALYSIS OF RECRUITMENT PERIOD 
Juan J Gagliardino
1*
, Jorge F Elgart
1
, Marcelo Bourgeois
2
, Graciela Etchegoyen
2
, Gabriel 
Fantuzzi
1
, Matías Ré
1
, Juan P Ricart
1
, Silvia García
1
, Cecilia Giampieri
1
, Lorena González
1
, 
Florencia Suárez-Crivaro
3
, Peter Kronsbein
4
, Julieta M Angelini
5
, Camilo Martínez
5
, Jorge 
Martínez
5
, Alberto Ricart
6 
and Eduardo Spinedi
1
 
 
1
CENEXA. Center for Experimental and Applied Endocrinology (UNLP-CONICET La 
Plata), Faculty of Medical Sciences (UNLP), La Plata, Argentina; 
2
Chair of Epidemiology - 
INUS Center, Faculty of Medical Sciences (UNLP), La Plata, Argentina; 
3
Laboratory, 
Secretariat of Health and Social Medicine, Municipality of La Plata, La Plata, Argentina; 
4
Faculty of Nutrition, Food and Hospitality Sciences, Niederrhein University of Applied 
Sciences, Mönchengladbach, Germany; 
5
Faculty of Medical Sciences, National University of 
La Plata (UNLP), La Plata, Argentina; 
6
IdIHCS. Institute of Research in Humanities and 
Social Sciences (UNLP-CONICET La Plata), Faculty of Humanities and Cs of Education 
(UNLP), La Plata, Argentina. 
 
Running title: Primary prevention of diabetes 
 
*Address for Correspondence:  
Dr. Juan J. Gagliardino,  
CENEXA (UNLP-CONICET La Plata), Facultad de Ciencias Médicas - UNLP.   
60 y 120 – 4to. Piso, (1900) La Plata, Argentina.  
Fax: (54-221) 422-2081  
e-mail: cenexaar@yahoo.com.ar 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved. 
Abstract word counts: 245 
Text word counts: 2,151 
Number of tables/figures: 4 
Number of references: 21 
Abstract  
Objectives: Primary Prevention of Diabetes Program in Buenos Aires Province (PPDBA) 
evaluates the effectiveness of adopting healthy lifestyle to prevent type 2 diabetes (T2D) in 
people at high risk of developing it. We aimed to present preliminary data analysis of 
FINDRISC and laboratory measurements taken during recruitment of people for the PPDBA 
in the cities of La Plata, Berisso and Ensenada, Argentina. 
Methods: People were recruited through: Population approach (house to house survey by 
FINDRISC in randomized areas) and opportunistic approach (FINDRISC completed by 
participants during consultations for non-related pre-diabetes/diabetes symptoms in public 
and private primary care centers of cities involved). In people with FINDRISC score ≥13 
points we evaluated blood concentrations of HbA1c, creatinine, lipids and an oral glucose 
tolerance test (OGTT). 
Results: 3415 individuals completed the FINDRISC populational survey and 344 the 
opportunistic survey; 43% of the two groups scored over 13 points; 2.8 and 75.4% of them, 
respectively, took the prescribed OGTT. 53.7% of the OGTT showed normal values and 
5.2% unknown T2D. The remaining cases showed 69.5% impaired fasting glucose (IFG), 
13.6% impaired glucose tolerance (IGT) and 16.9% both impairements. HbA1c values 
showed significant differences compared to normal glucose tolerance (NGT; 4.96±0.43%), 
pre-diabetes (5.28±0.51%) and T2D (5.60±0.51%). Participants with pre-diabetes and T2D 
showed a predominant increase in LDL-cholesterol values. In pre-diabetes, > 50% showed 
insulin resistance (IR). 
Conclusions: People with pre-diabetes/T2D had dyslipidemia associated with IR which 
promotes the development of T2D and cardiovascular disease. Thus, it merits its appropriate 
treatment. 
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1. INTRODUCTION  
Diabetes prevalence in Argentina grew from 8.4 to 9.8% between 2005 and 2013 [1], mainly 
conditioned by type 2 diabetes (T2D). The frequent association of T2D with other 
cardiovascular risk factors (CVRF) facilitates development/progression of chronic 
complications responsible for their high morbidity and mortality and economic cost [2,3].  
T2D develops in people with genetic predisposition exposed to unhealthy diets and physical 
inactivity [4]; therefore, adoption of healthy lifestyles is the most effective way to prevent the 
disease, a concept supported by the successful reduction, up to 58%, of T2D development 
through implementation of primary prevention programs in different countries and ethnical 
groups [5]. Based on such experience, there is a strong European movement towards 
promoting diabetes prevention programmes implementation in their region that even has 
developed a tool kit to use for that purpose [6]. Despite strong evidence of the preventive 
effectiveness of lifestyle changes in people at high risk of developing T2D, before 
implementing such programs at national level, it is necessary to verify how they work in our 
environment, identify potential difficulties/barriers to preventive goals to avoid or neutralize 
them, and estimate the program’s cost. 
Consequently, and given the lack of national evidence, we initiated the Pilot Program for 
Primary Prevention of Diabetes of Buenos Aires Province (PPDBA), aiming to evaluate the 
effectiveness of healthy lifestyle adoption on the clinical manifestation of T2D in people at 
increased risk of developing the disease. This report shows preliminary analysis of data 
obtained during recruitment of people for the PPDBA in three cities of Buenos Aires 
province. 
 
2. MATERIALS AND METHODS  
The characteristics of the PPDBA were previously reported [7]. Briefly, it is a prospective, 
randomized cohort study to evaluate the benefits of adopting healthy lifestyles (healthy meal 
plan and regular practice of physical activity) on the transition from pre-diabetes (impaired 
glucose tolerance [IGT], impaired fasting glycaemia [IFG], or both) to T2D.  This study 
recruits men and women between 45 and 75 years of age with pre-diabetes according to the 
American Diabetes Association (ADA) and European Association for the Study of Diabetes 
(EASD)[8] in three municipalities of Buenos Aires province (La Plata, Berisso and 
Ensenada). For recruitment we used two different procedures: 
1. Populational approach: we randomly selected census areas in each municipality as 
explained in the previous publication [7]; in these areas, previously trained students of the 
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last year of the School of Medicine of La Plata National University visited homes to 
administer the FINDRISC [9]. 
2. Opportunistic approach: This scheme was used previously for pre-diabetes and 
cardiovascular risk factor detection [10]; in our case, people visiting a physician’s office for 
reasons other than pre-diabetes/diabetes filled out the FINDRISC. To facilitate this approach 
we invited physicians in Primary Care Centers (CAPs) of the participant municipalities and in 
private groups in La Plata. Consequently, the sample included persons from both public 
health and social security sectors. 
In both approaches, people with a FINDRISC score ≥13 points (cut-off value indicated by 
Prof. Jakko Tuomilheto, PPDBA advisor) were invited to receive free of charge an oral 
glucose tolerance test (OGTT) following WHO recommendations [11]. In the OGTT fasting 
blood sample we also measured concentrations of HbA1c (by HPLC technique), creatinine, 
total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride using commercial kits. 
All blood samples were processed in a single laboratory (CentraLab, CABA, Argentina) 
within 24 hours after extraction. 
People with normal glucose tolerance (NGT) were advised to repeat the OGTT in one year, 
whereas those with a diagnosis of T2D were referred to their own physician for appropriate 
treatment. Those who presented pre-diabetes (IFG, IGT or both) and met the PPDBA 
inclusion criteria were invited to participate in the PPDBA after acceptance and signing of the 
informed consent. Thereafter, these people were randomly assigned to one of our two study 
groups (Intensified and Self-administered intervention) as previously reported [7].  
 
2.1 Ethical issue 
The study protocol was analyzed and approved by the Bioethical Committee of the National 
University of La Plata and the Central Ethics Committee of the Ministry of Health of the 
province of Buenos Aires. The study was developed according to the Good Practice 
Recommendations (International Harmonisation Conference) and the ethical guidelines of the 
Helsinki Declaration. All subjects gave their written informed consent to participate in the 
study, and this was signed before blood samples were collected. 
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2.2 Statistical analysis 
With the FINDRISC and laboratory data collected during the early recruitment period (2014-
2015), a descriptive and inferential statistical analysis was performed using SPSS (Statistical 
Package for Social Sciences), version 15.0 for Windows (SPSS Inc, Chicago, IL, US). 
Continuous variables are presented as means and standard deviations (SD) and categorical 
variables as proportions. Differences in continuous variables were assessed using parametric 
and non-parametric tests according to the normal distribution of the variables (Kolmogorov-
Smirnoff test), using the χ² test to evaluate the differences in proportions. Differences with p 
values <0.05 were considered significant.. 
 
3. RESULTS 
FINDRISC: 3415 questionnaires were completed with the Populational approach and 344 
with the opportunistic one. Their results showed a normal distribution with 43% of 
participants scoring ≥13 points; 23% and 3%, respectively, had high and very high scores of 
risk (FINDRISC criteria) [9]) of developing T2D (Figure 1). Whereas in the populational 
approach only 2.8% of people prescribed the OGTT did it, 75.4% of people in the 
opportunistic approach in the same condition took the OGTT. 
Comparing FINDRISC results from people below and above 13 points, we found an 
asymmetric percentage distribution of each of the 8 questions within the two groups: people 
in the latter group had a higher percentage of: 
• physical inactivity 
• medication taken to control blood pressure 
• age (were older) 
• BMI corresponding to overweight/obesity 
• waist circumference above the normal cut-off value 
• low daily consumption of fruits and vegetables 
• history of hyperglycemia. 
The largest percentage corresponded to waist circumference (81%) and physical inactivity 
(74%) while history of hypoglycemia was recorded only in 20% of the this group. 
According to the OGTT results and cut-off values suggested by the ADA-EASD, our sample 
included three categories of people: 1) with normal glucose tolerance (NGT), 2) with pre-
diabetes (IFG/IGT or both) and 3) with undiagnosed/untreated T2D (Figure 2). Although we 
only prescribed OGTT for people with a score ≥13, 53.7% of them showed normal results. 
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Figure 2 also shows that 5.2% of the individuals evaluated had unknown/ undiagnosed and 
consequently untreated T2D. Further data analysis showed that in 63% of cases of T2D and 
in 62% of pre-diabetes identified, diagnosis was based on the fasting blood glucose value of 
the OGTT. 
HbA1c values recorded to date showed significant differences when comparing the 3 
following groups: people with NGT (4.96±0.43%), with pre-diabetes (5.28±0.51%) and with 
T2D (5.60±0.51%) (Figure 3). 
Participants with pre-diabetes and T2D showed a similar abnormal lipid profile characterized 
by total cholesterol, LDL-c and triglyceride levels above those recommended by international 
guidelines (Table 1). Increased LDL-c levels was the most frequently detected change in the 
pre-diabetes group, this frequency comparable to that observed in people with T2D. 
We did not measure insulinemia, therefore, we have no direct indicator of insulin resistance 
(IR) in people with pre-diabetes. We instead used two indirect measures: a clinical (waist 
circumference) [12] and a laboratory test (Triglyceride/HDL-c ratio) using cut-off values 
validated in our population [13]. According to waist circumference (men> 102 and women> 
88 cm), 78% of participants with pre-diabetes had IR whereas that figure was 51% for the 
Triglyceride/HDL-c ratio (values >3.5 and >2.5 for men and women, respectively). Thus, 
independent of the index applied, more than half of our pre-diabetes population displayed IR. 
 
4. DISCUSSION  
Current PPDBA data show: barriers to participants’ recruitment; evidence of diabetes 
diagnostic inefficiency in our care system; and some novel data. 
While the FINDRISC data shows similar results for the two collection approaches, adherence 
to OGTT prescription was significantly higher with the opportunistic approach (75.4 vs. 
2.8%). Adherence failure could be attributed to: a) subjectively "healthy" persons reject the 
diagnosis of a serious but asymptomatic disease after a medical student asked 8 questions; b) 
inadequate population and health system promotion of preventive practices considering the 
absence of symptoms (especially pain); and c) the subjective inclination to follow their 
physician’s prescriptions more readily than those of an unfamiliar health agent. Therefore, the 
opportunistic rather than the populational approach is more advisable for use in similar 
studies implemented in our culture.  
FINDRISC, with low cost and easy performance, decreased the prescription of OGTT (57%), 
thereby optimizing resources. Although the weakness of this assumption is that the 
FINDRISC has not yet been validated in our local population, it has been used in Caucasian, 
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Spanish and other Latin American populations [14]; these studies also yielded data 
comparable to those currently recorded. In any case, the cut-off value currently used rendered 
53.7% of normal OGTT, thus it would require an adaptation of this value to our population in 
order to optimize outcomes. This assumption is supported by some European 
authors´conclusions that the FINDRISC is currently the best available tool for use in clinical 
practice but may require modifications if applied to different ethnic groups [15]. The 
asymmetry of positive answers in people below and above the cut-off value indicates that this 
adaptation requires recalculation of the weight given to each question and then the resetting 
of the cut-off value according to the results of the OGTT. However, for the time being, the 
FINDRISC with its current score is still a useful and effective tool at the primary care level. 
Another important aspect of our FINDRISC data analysis is that family history of diabetes, 
which represents the effect of inheritance on the incidence of pre-diabetes/T2D development, 
is reported by people at high risk in a markedly lower proportion than waist circumference 
and physical inactivity related to the mass and function of visceral adipose tissue and 
metabolic modulators released by physical activity. These data support the concept that 
epigenetic alterations facilitate the development of pre-diabetes and its progression to T2D 
[16,17].  
The 3 different pre-diabetes stages identified by OGTT (IFG, IGT, and both) have a different 
annual transition rate to T2D: 12% for the third stage and 4 and 6% for the other two, 
respectively [18]. Therefore, the implementation of preventive strategies is correspondingly 
more or less imperative. In our case, most people with dysglycemia presented IFG (69.5%), a 
finding also reported by other authors who showed that these people have significantly larger 
values of waist circumference, blood pressure and frequency of dyslipidemia and 
cardiovascular disease [19]. It has been also reported that they have already lost 50% of their 
β-cell mass [20]. Thus, when planning to implement a primary prevention intervention and having 
low availability of human and economic resource, systematic measurement of fasting blood glucose 
might be an incomplete but still reasonable approach to identify people with pre-diabetes.  
Using the sequence FINDRISC-OGTT we identified 5% of people with T2D who were 
unaware of their disease and untreated; these results could suggest the advisability of 
systematic prescription of OGTT for diabetes detection. However, 63% of people with 
undiagnosed with T2D and 62% of those with pre-diabetes were identified by fasting 
glycemia values. Therefore, ongoing awareness of health care team members concerning the 
importance of careful analysis of fasting blood glucose values by searching for diagnostic 
values recommended by national and international guidelines could overcome the problem. 
 
This article is protected by copyright. All rights reserved. 
The importance of this awareness is further supported by the report that late diagnosis 
increases the risk of cardiovascular morbidity and mortality more than late treatment [21]. 
Based on the recommendations of the Experts Committee convened by ADA, EASD and 
International Diabetes Federation (IDF) to redefine diabetes diagnosis by HbA1c values [22], 
different countries established their own cut-off values for pre-diabetes and T2D diagnosis. 
Current HbA1c values result from the first local study of this type.  
Participants with pre-diabetes and T2D displayed similar dyslipidemia characterized by 
abnormal changes in all lipid fractions; an increase in the LDL-c fraction was the most 
frequently detected, indicating a high risk for developing atherosclerotic cardiovascular 
disease (CVD). Thus, pre-diabetes stage is a risk for developing T2D but also for CVD [23]. 
Since we found no marked differences between the frequency of increased LDL-c in people 
with pre-diabetes and T2D, its presence in the former stage could be more a cause than a 
consequence of β-cell dysfunction. Identification of plasma lipoprotein receptor in pancreatic 
β cells involved in their binding/processing and the report that LDL particles reduce insulin 
mRNA levels, β-cell proliferation, and induce a dose-dependent increase in their apoptotic 
rate support this assumption. Conversely, HDL-c particles antagonize the proapoptotic effect 
of LDL-c. Therefore, the deleterious effect of increased LDL-c on β-cell function/mass could 
be potentiated by the simultaneous decrease in HDL-c concentration [24,25]. 
Finally, using two indirect measurements (waist circumference and TG/HDL-c ratio), we 
demonstrated that most people with pre-diabetes have IR. 
We recognize that although our evidence is clear, it is based on certain circumstances and on 
a low number of cases. However, its statistical significance suggests that it is unlikely to be 
the result of chance.  
In conclusion, early results of PPDBA implementation demonstrate that: 1) sequential 
performance of FINDRISC-OGTT is an effective strategy to identify people with pre-
diabetes or T2D who were unaware of their disease; 2) people with pre-diabetes present a 
state of IR associated with dyslipidemia that favors development of T2D and CVD, thus this 
a stage of disease rather than pre-disease stage that merits its immediate treatment; 3) in our 
media, and probably in other ones with similar socioeconomic characteristics, the 
opportunistic approach implemented through primary care physicians was a more effective 
strategy to identify people with pre-diabetes; 4) health authorities must be aware of pre-
diabetes and T2D underestimation occurring at the primary care level in order to correct this 
deficiency; and 5) final PPDBA data will more accurately define national HbA1c cut-off 
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values for pre-diabetes and T2D diagnosis. Our data contribute to develop effective strategies 
to decrease the diabetes burden.  
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Table 1. Lipid profile of the different subgroups of pre-diabetes and T2D 
Fraction / Condition  IFG 
(n=71) 
IGT 
(n=15) 
Both 
(n=19) 
T2D 
(n=15) 
Total Cholesterol (mg/dl)  Mean ± SD 197 ± 39 208 ± 30 205 ± 58 215 ± 52 
 %* 44 60 47 47 
c-HDL (Men)  Mean ± SD 44 ± 14 -- 42 ± 10 59 ± 27 
 %** 29  44 33 
c-HDL (Women)  Mean ± SD 53 ± 15 51 ± 15 57 ± 14 53 ± 18 
 %** 36 53 50 58 
c-LDL Mean ± SD 119 ± 37 128± 20 127 ± 51 129 ± 41 
 %
#
 59 87 68 71 
Triglycerides Mean ± SD 154 ± 98 144 ± 68 165 ± 61 163 ± 115 
 %
†
 38 33 47 40 
Mean ± standard deviation (SD). Values represent % of people with values of * Total Cholesterol > 200 mg/dL; 
** c-HDL < 50 mg/dl (female) and < 40 mg/dl (male); # c-LDL > 100 mg/dL and † Triglycerides (TG) > 150 
mg/dL. 
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Figure 1. Distribution of risk percentage of FINDRISC 
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Figure 2. Results of the OGTT N (total) = 287; N (Pre-diabetes) = 118 
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Figure 3. HbA1c differences by category.Values are mean ± standard deviation (N=group 
size, in parentheses). 
 
